Scarica l'app Stockscreener
0.6581
9.53%
0.0571
Precedente Chiudi:
$0.601
Aprire:
$0.62
Volume 24 ore:
714.96K
Relative Volume:
2.03
Capitalizzazione di mercato:
$55.59M
Reddito:
$5.12M
Utile/perdita netta:
$-67.00M
Rapporto P/E:
-0.4477
EPS:
-1.47
Flusso di cassa netto:
$-38.94M
1 W Prestazione:
+9.71%
1M Prestazione:
+21.74%
6M Prestazione:
-6.31%
1 anno Prestazione:
-91.19%
Intervallo 1D:
$0.5811
$0.659
Intervallo di 1 settimana:
$0.5226
$0.6741
Portata 52W:
$0.3816
$8.98
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Nome
Verrica Pharmaceuticals Inc
Settore
Industria
Telefono
484-453-3300
Indirizzo
10 NORTH HIGH STREET, WEST CHESTER, PA
Confronta VRCA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
0.6575 | 55.59M | 5.12M | -67.00M | -38.94M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
548.99 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.86 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
549.93 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.88 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-06 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Aggiornamento | Needham | Hold → Buy |
| 2023-03-22 | Iniziato | Jefferies | Buy |
| 2023-02-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-12-24 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-06-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-24 | Iniziato | Northland Capital | Outperform |
| 2020-03-24 | Iniziato | Needham | Buy |
| 2019-02-21 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Verrica Pharmaceuticals Inc Borsa (VRCA) Ultime notizie
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Significant Decline in Short Interest - Defense World
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results - Barchart.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of “Hold” by Brokerages - Defense World
Shareholders May Not Overlook Verrica Pharmaceuticals Insiders Selling US$1.1m In Stock - simplywall.st
Verrica Pharmaceuticals amends credit agreement By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Amends Credit Agreement with OrbiMed - TipRanks
Verrica Pharmaceuticals amends credit agreement - Investing.com
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA): Are Analysts Optimistic? - Yahoo Finance
Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% – Here’s Why - Defense World
Verrica Pharmaceuticals Holds Annual Stockholders Meeting - TipRanks
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York - GlobeNewswire
Verrica Pharmaceuticals CEO Reveals Dermatology Pipeline Updates at Jefferies Healthcare Conference - Stock Titan
Verrica Pharmaceuticals (NASDAQ:VRCA) Upgraded at Wall Street Zen - Defense World
Brokerages Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Target Price at $8.00 - Defense World
Verrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in Pipeline - MSN
Verrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTH - MSN
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail
Verrica Pharmaceuticals’ SWOT analysis: stock faces cash crunch amid YCANTH growth - Investing.com Canada
Verrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of Directors - MSN
Verrica reports high response rate in skin cancer study - MSN
Research Analysts Offer Predictions for VRCA Q2 Earnings - Defense World
Needham & Company LLC Reiterates “Hold” Rating for Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica signals sustainable growth trajectory as YCANTH revenues surpass $3M and Phase 3 milestone looms - MSN
RBC Capital Reaffirms Their Hold Rating on Verrica Pharmaceuticals (VRCA) - The Globe and Mail
Verrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate Update - MSN
Verrica Pharmaceuticals (VRCA) Sees Q1 Revenue Growth Driven by YCANTH - GuruFocus
Verrica Pharmaceuticals (VRCA) Receives Hold Rating from Needham - GuruFocus
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates - MSN
Verrica Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... - Yahoo Finance
Verrica Pharmaceuticals Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Verrica Pharmaceuticals Q1 2025 results show revenue growth By Investing.com - Investing.com South Africa
Verrica Pharmaceuticals Q1 2025 Earnings: EPS Misses, Revenue Su - GuruFocus
Earnings call transcript: Verrica Pharmaceuticals Q1 2025 results show revenue growth - Investing.com India
Verrica Pharmaceuticals (VRCA) Reports Strong Q1 Revenue and Adv - GuruFocus
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results - The Manila Times
West Pharmaceutical Services to Present at Upcoming Healthcare and Growth Stock Conferences - MyChesCo
Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result - GuruFocus
Verrica Pharmaceuticals (VRCA) Expected to Announce Earnings on Tuesday - Defense World
Head-To-Head Comparison: KalVista Pharmaceuticals (NASDAQ:KALV) and Verrica Pharmaceuticals (NASDAQ:VRCA) - Defense World
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call Transcript - MSN
Verrica Pharmaceuticals at The Citizens JMP Life Sciences Conference: Strategic Developments in Dermatology - Investing.com Canada
Verrica Pharmaceuticals Inc Azioni (VRCA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Verrica Pharmaceuticals Inc Azioni (VRCA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hayes Christopher G. | CHIEF LEGAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
26,183 |
69,647 |
115,303 |
| Hayes Christopher G. | CHIEF LEGAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
9,530 |
23,444 |
105,773 |
| Goldenberg Gary | Chief Medical Officer |
Aug 26 '24 |
Sale |
2.66 |
9,888 |
26,302 |
97,862 |
| Goldenberg Gary | Chief Medical Officer |
Aug 27 '24 |
Sale |
2.46 |
3,601 |
8,858 |
94,261 |
| Bonaccorso Joe | CHIEF COMMERCIAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
24,709 |
65,726 |
82,107 |
| Bonaccorso Joe | CHIEF COMMERCIAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
8,993 |
22,123 |
73,114 |
| Kohler Terry | CHIEF FINANCIAL OFFICER |
Aug 26 '24 |
Sale |
2.66 |
21,820 |
58,041 |
52,596 |
| Kohler Terry | CHIEF FINANCIAL OFFICER |
Aug 27 '24 |
Sale |
2.46 |
7,899 |
19,432 |
44,697 |
| White Ted | PRESIDENT AND CEO |
Aug 26 '24 |
Sale |
2.66 |
24,979 |
66,444 |
224,988 |
| White Ted | PRESIDENT AND CEO |
Aug 27 '24 |
Sale |
2.46 |
9,021 |
22,192 |
215,967 |
1.28%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):